"ビオンテック" の関連情報検索結果

MediLink Therapeutics Announces Strategic Collaboration and Worldwide License Agreement with BioN...



MediLink Therapeutics Announces Strategic Collaboration and Worldwide License Agreement with BioNTech to develop next-generation anti-cancer antibody-drug conjugate  PR Newswire

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine - The New England Journal of Medicine



Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine  The New England Journal of Medicine

FDA puts clinical hold on BioNTech’s malaria vaccine trial - Clinical Trials Arena



FDA puts clinical hold on BioNTech’s malaria vaccine trial  Clinical Trials Arena

BioNTech’s RNA vaccine sparks potential in pancreatic cancer - Pharmaceutical Technology



BioNTech’s RNA vaccine sparks potential in pancreatic cancer  Pharmaceutical Technology

Hackers breach Pfizer/BioNTech COVID-19 vaccine data in cyberattack targeting EMA - Fierce Pharma



Hackers breach Pfizer/BioNTech COVID-19 vaccine data in cyberattack targeting EMA  Fierce Pharma

BioNTech Builds Case for PD-L1/VEGF Bispecific With Promising Breast Cancer Data - BioSpace



BioNTech Builds Case for PD-L1/VEGF Bispecific With Promising Breast Cancer Data  BioSpace

The FDA OKs Pfizer-BioNTech Booster For People 65+ Or At High Risk For Severe COVID - NPR



The FDA OKs Pfizer-BioNTech Booster For People 65+ Or At High Risk For Severe COVID  NPR

symbol__ Stock Quote Price and Forecast - CNN



symbol__ Stock Quote Price and Forecast  CNN

Bayer Partners with BioNTech to Develop mRNA Vaccines, Drugs for Animal Health - Genetic Engineer...



Bayer Partners with BioNTech to Develop mRNA Vaccines, Drugs for Animal Health  Genetic Engineering and Biotechnology News

Pfizer/BioNTech bivalent COVID-19 booster approved by UK medicines regulator - GOV.UK



Pfizer/BioNTech bivalent COVID-19 booster approved by UK medicines regulator  GOV.UK

4 Coronavirus Vaccine Stocks the Bill & Melinda Gates Foundation Is Betting On - The Motley Fool



4 Coronavirus Vaccine Stocks the Bill & Melinda Gates Foundation Is Betting On  The Motley Fool